An Opportunity To Grow In Pfizer Inc. (PFE) Price
Pfizer Inc. (NYSE: PFE) announced the successful completion of clinical studies for a novel Lyme disease vaccine. Despite a 3% drop in the S&P 500, the vaccine has significant commercial potential, which has boosted the stock. In collaboration with Valneva SE (VALN), Pfizer is developing a VLA15 vaccine. The VLA15 vaccination elicited a significant immunological […]